GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » PAVmed Inc (NAS:PAVM) » Definitions » EBIT

PAVmed (PAVmed) EBIT : $-75.14 Mil (TTM As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is PAVmed EBIT?

PAVmed's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-18.50 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-75.14 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. PAVmed's annualized ROC % for the quarter that ended in Mar. 2024 was -100.06%. PAVmed's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -1,283.22%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. PAVmed's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -168.57%.


PAVmed EBIT Historical Data

The historical data trend for PAVmed's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PAVmed EBIT Chart

PAVmed Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -17.24 -35.84 -56.13 -101.96 -78.67

PAVmed Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -22.03 -17.66 -21.59 -17.39 -18.50

Competitive Comparison of PAVmed's EBIT

For the Medical Devices subindustry, PAVmed's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PAVmed's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, PAVmed's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where PAVmed's EV-to-EBIT falls into.



PAVmed EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-75.14 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PAVmed  (NAS:PAVM) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

PAVmed's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=-56.144 * ( 1 - 0% )/( (57.67 + 54.553)/ 2 )
=-56.144/56.1115
=-100.06 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

PAVmed's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-73.984/( ( (6.05 + max(-3.553, 0)) + (5.481 + max(-4.104, 0)) )/ 2 )
=-73.984/( ( 6.05 + 5.481 )/ 2 )
=-73.984/5.7655
=-1,283.22 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.061 + 0.539 + 4.259) - (5.128 + 0 + 3.284)
=-3.553

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.067 + 0.668 + 3.303) - (8.142 + 0 + 0)
=-4.104

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

PAVmed's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=-75.14/44.576
=-168.57 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PAVmed EBIT Related Terms

Thank you for viewing the detailed overview of PAVmed's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


PAVmed (PAVmed) Business Description

Traded in Other Exchanges
N/A
Address
360 Madison Avenue, 25th Floor, New York, NY, USA, 10017
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The Company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard and the Veris Cancer Care Platform.
Executives
Michael J Glennon director 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Michael Adam Gordon officer: General Counsel ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Shaun O'neil officer: Chief Operating Officer ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
James L Cox director 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Debra White director C/O PAVMED INC., ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Ronald M Sparks director 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Brian J. Deguzman officer: Chief Medical Officer 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Dennis M Mcgrath officer: President & CFO C/O PAVMED INC., ONE GRAND CENTRAL PLACE, STE. 4600, NEW YORK NY 10165
Lishan Aklog director, 10 percent owner, officer: Chairman and CEO 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10171
Joan B Harvey director ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Timothy E Baxter director ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Matthew Sirovich 10 percent owner C/O SCOPIA MANAGEMENT INC, 450 SEVENTH AVENUE, 43RD FLOOR, NEW YORK NY 10123
Ira Scott Greenspan director 888 SEVENTH AVENUE, 9TH FLOOR, NEW YORK NY 10106
David S. Battleman director C/O TRUENORTH LIFESCIENCES, 348 WEST 57TH STREET, #226, NEW YORK NY 10019
Joshua R Lamstein director 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170